CHAMPIONS ONCOLOGY, INC. Contract Liability (Deferred Revenue)
CHAMPIONS ONCOLOGY, INC. (CSBR) had Contract Liability (Deferred Revenue) of $9.55 million as of 2026-07-31, per its 10-Q filed 2026-09-11.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2026-09-11
- 2026-07-31: Contract with Customer, Liability, Current $9.55M.
- 2026-04-30: Contract with Customer, Liability, Current $8.83M.
- 2026-01-31: Contract with Customer, Liability, Current $10.00M.
- 2025-10-31: Contract with Customer, Liability, Current $12.34M.
| Period end | Contract with Customer, Liability, Current | Contract with Customer, Liability, Current as first filed |
|---|---|---|
| 2026-07-31 | $9.55M 10-Q · filed 2026-09-11 | |
| 2026-04-30 | $8.83M 10-Q · filed 2026-09-11 | |
| 2026-01-31 | $10.00M 10-Q · filed 2026-03-12 | |
| 2025-10-31 | $12.34M 10-Q · filed 2025-12-15 | |
| 2025-07-31 | $14.43M 10-Q · filed 2025-09-15 | |
| 2025-04-30 | $15.44M 10-K · filed 2026-07-27 | |
| 2025-01-31 | $10.92M 10-Q · filed 2025-03-17 | |
| 2024-10-31 | $10.22M 10-Q · filed 2024-12-16 | |
| 2024-07-31 | $10.31M 10-Q · filed 2024-09-13 | |
| 2024-04-30 | $12.09M 10-K · filed 2025-07-23 | |
| 2024-01-31 | $13.33M 10-Q · filed 2024-03-15 | |
| 2023-10-31 | $13.00M 10-Q · filed 2024-03-15 | $12.97M 10-Q · filed 2023-12-13 |
| 2023-07-31 | $11.10M 10-Q · filed 2023-12-13 | $11.14M 10-Q · filed 2023-09-13 |
| 2023-04-30 | $12.78M 10-K · filed 2024-07-19 | |
| 2023-01-31 | $13.16M 10-Q · filed 2023-03-16 | |
| 2022-10-31 | $11.20M 10-Q · filed 2024-03-15 | $11.19M 10-Q · filed 2022-12-13 |
| 2022-07-31 | $10.90M 10-Q · filed 2023-12-13 | $10.88M 10-Q · filed 2022-09-12 |
| 2022-04-30 | $11.10M 10-Q · filed 2024-03-15 | $11.07M 10-K · filed 2022-07-22 |
| 2022-01-31 | $8.70M 10-Q · filed 2022-03-15 | |
| 2021-10-31 | $6.13M 10-Q · filed 2021-12-13 | |
| 2021-07-31 | $5.48M 10-Q · filed 2021-09-13 | |
| 2021-04-30 | $6.26M 10-K · filed 2022-07-22 | |
| 2021-01-31 | $6.62M 10-Q · filed 2021-03-15 | |
| 2020-10-31 | $6.19M 10-Q · filed 2020-12-14 | |
| 2020-07-31 | $5.67M 10-Q · filed 2020-09-14 | |
| 2020-04-30 | $5.80M 10-K · filed 2022-07-22 | $5.82M 10-K · filed 2020-07-28 |
| 2020-01-31 | $4.59M 10-Q · filed 2020-03-16 | |
| 2019-10-31 | $4.15M 10-Q · filed 2019-12-16 | |
| 2019-07-31 | $3.97M 10-Q · filed 2019-09-16 | |
| 2019-04-30 | $4.02M 10-K · filed 2020-07-28 | |
| 2019-01-31 | $4.72M 10-Q · filed 2019-03-18 | |
| 2018-10-31 | $4.83M 10-Q · filed 2018-12-17 | |
| 2018-07-31 | $4.26M 10-Q · filed 2018-09-14 | |
| 2018-04-30 | $4.70M 10-Q · filed 2019-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |